Altimmune (ALT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Apr, 2026Opening remarks and agenda
Meeting called to order by the Chairman and held virtually to increase inclusivity and participation.
Formal business outlined in the notice and proxy statement sent to shareholders of record as of March 13, 2026.
Directors, officers, independent auditors, and legal counsel introduced at the start.
Corporate governance
Voting limited to shareholders of record as of March 13, 2026, with procedures for proxy and web portal voting explained.
Quorum established with 88,270,241 shares represented out of 130,105,177 entitled to vote.
Inspector of Election appointed to tabulate results and ensure procedural compliance.
Board and executive committee updates
Nine nominees for director positions presented, all current directors, with no outside nominations received.
Board unanimously recommended voting in favor of all proposals.
Latest events from Altimmune
- Phase III MASH trial enrollment begins this year, with key data readouts for new indications next quarter.ALT
Goldman Sachs 47th Annual Global Healthcare Conference 202610 Jun 2026 - Pemvidutide's phase III MASH trial advances with strong data, funding, and regulatory alignment.ALT
Jefferies Global Healthcare Conference 20264 Jun 2026 - Pemvidutide delivers robust efficacy and safety in liver disease, advancing to Phase 3 trials.ALT
Corporate presentation4 Jun 2026 - Cash reserves surged to $535M, enabling major clinical milestones for pemvidutide in 2026.ALT
Q1 202613 May 2026 - Pemvidutide advances with strong MASH data, regulatory alignment, and promising new indications.ALT
Leerink Global Healthcare Conference 20269 May 2026 - Proxy covers director elections, auditor ratification, compensation, and capital structure changes.ALT
Proxy Filing17 Mar 2026 - Pemvidutide advances with strong MASH data, AI-driven phase III, and expanding late-stage pipeline.ALT
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - Pemvidutide advances to phase III in MASH, targeting efficacy, tolerability, and market differentiation.ALT
The Citizens Life Sciences Conference 202610 Mar 2026 - Pemvidutide shows robust efficacy and safety in liver disease, advancing to Phase 3 trials.ALT
Corporate presentation10 Mar 2026